Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

Activation of the PI3K (phosphoinositide 3-kinase) pathway is a frequent occurrence in human tumors and is thought to promote growth, survival, and resistance to diverse therapies. Here, we report pharmacologic characterization of the pyridopyrimidinone derivative XL765 (SAR245409), a potent and highly selective pan inhibitor of class I PI3Ks (α, β, γ, and δ) with activity against mTOR. Broad kinase selectivity profiling of >130 protein kinases revealed that XL765 is highly selective for class I PI3Ks and mTOR over other kinases. In cellular assays, XL765 inhibits the formation of PIP3 in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 phosphorylation in multiple tumor cell lines with different genetic alterations affecting the PI3K pathway. In a panel of tumor cell lines, XL765 inhibits proliferation with a wide range of potencies, with evidence of an impact of genotype on sensitivity. In mouse xenograft models, oral administration of XL765 results in dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6 with a duration of action of approximately 24 hours. Repeat dose administration of XL765 results in significant tumor growth inhibition in multiple human xenograft models in nude mice that is associated with antiproliferative, antiangiogenic, and proapoptotic effects. Mol Cancer Ther; 13(5); 1078–91. ©2014 AACR.

[1]  M. Prados,et al.  Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. , 2013 .

[2]  J. Lee,et al.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.

[3]  Wei Xu,et al.  Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[4]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[5]  M. Peppelenbosch,et al.  The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling , 2011, Oncogene.

[6]  Miyuki Yoshida,et al.  The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations , 2011, Clinical Cancer Research.

[7]  Mitchel S. Berger,et al.  Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. , 2011, Neuro-oncology.

[8]  P. Dennis,et al.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.

[9]  K. M. Chen,et al.  Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma , 2011, Clinical Cancer Research.

[10]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[11]  Jie Qi,et al.  Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.

[12]  C. García-echeverría.  Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. , 2010, Bioorganic & medicinal chemistry letters.

[13]  Dihua Yu,et al.  PI(3)King Apart PTEN's Role in Cancer , 2010, Clinical Cancer Research.

[14]  M. Duffy,et al.  Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.

[15]  M. Belvin,et al.  Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.

[16]  J. Dancey.  mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.

[17]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[18]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[19]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[20]  T. Roberts,et al.  Should individual PI3 kinase isoforms be targeted in cancer? , 2009, Current opinion in cell biology.

[21]  A. Levitzki,et al.  Targeting the EGFR and the PKB pathway in cancer. , 2009, Current opinion in cell biology.

[22]  M. Murawska,et al.  PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients , 2009, Cancer biology & therapy.

[23]  B. Jiang,et al.  PI3K/PTEN signaling in angiogenesis and tumorigenesis. , 2009, Advances in cancer research.

[24]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[25]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[26]  C. Benes,et al.  Class 1A PI3K regulates vessel integrity during development and tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[27]  K. Okkenhaug,et al.  The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ , 2008, Proceedings of the National Academy of Sciences.

[28]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[29]  F. Yakes,et al.  Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647 , 2007, Clinical Cancer Research.

[30]  A. Paradiso,et al.  Preferential chemosensitization of PTEN‐mutated prostate cells by silencing the Akt kinase , 2007, The Prostate.

[31]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[32]  S. Hirono,et al.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.

[33]  E. Robertson,et al.  Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. , 2005, Cancer research.

[34]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[35]  E. Nånberg,et al.  Role of phosphoinositide 3OH‐kinase in autocrine transformation by PDGF‐BB * , 2001, Journal of cellular physiology.

[36]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.